Loading stock data…
Latigo Biotherapeutics, Inc. (LTGO)
$23.73+0.69 (+2.99%)
Market ClosedLast close Sep 8
Latigo Biotherapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$23.44M↓ | -$21.51M |
| Net Income | -$22.96M↓ | -$20.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.39%
Volume
Today's trading volume
326,724
Recent News
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public offering, which raised over $85 billion in funding for Musk’s private space launch company, has accounted for the bulk of the first half’s IPO activity, but that is only part of the story. Even if you strip out SpaceX, the first half of this year saw new ‘traditional’ initial public offerings generate
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued
Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical data for its lead non opioid pain candidate LTG-001. See our latest analysis for Latigo Biotherapeutics. Since listing at US$18, Latigo Biotherapeutics’ share price has inched up to US$18.25, with a 1-day and year to date share price return of 1.39%, suggesting only early signs of momentum as...